Novo's Danish facility expansion will free up production capacity

A DKK 5.4bn (USD 740m) investment into expanding capacity will help enable the Danish drugmaker’s R&D division become API self-sufficient, which will hopefully benefit the production of existing drugs.

Photo: Tidsvilde Stine/Ritzau Scanpix

On Tuesday, Novo Nordisk announced it will expand its existing clinical API capacity in Bagsværd, a Copenhagen suburb, to improve the drugmaker’s capacity within research and development and clinical studies.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs